O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Pharmaceutical Sales Long Term Care Area Business Lead - CNS, First Line Manager

Full-TimeUpdated on 10/23/2026
$157.7k - $235.8k+ Incentive opportunity
Expert
Bachelor's, Master's, MBA
Remote in USA+4 moreMore locations: Houston, TX, USA | New Orleans, LA, USA | Dallas, TX, USA | Oklahoma City, OK, USA
Remote
Sales & Account ManagementField Sales, Account Management

About the job

Requirements
  • A bachelor's degree is required; an MBA or other related graduate degree is preferred.
  • Previous experience leading account managers or alliance/partnership managers, including developing and implementing account plans and contracting with health ecosystem players such as health systems or hospitals.
  • Previous cross-functional industry experience in commercial life sciences, such as pharmaceuticals or biotechnology, or a related industry engaging with key healthcare ecosystem players such as payers and health systems is a plus.
  • Ability to work in an ambiguous environment undergoing transformation is a strong plus.
  • A proven track record in coaching, training, and/or mentoring peers or others as assigned to help them meet or exceed goals, targets, and responsibilities.
  • A proven track record of consistently meeting or exceeding financial and/or other quantitative targets, as well as qualitative goals.
  • In-depth knowledge of strategy development, including contracting strategy, administration, and pull-through, is a strong plus.
  • Previous field sales management and/or marketing experience in the Neuroscience or Nephrology market, or a related industry, is preferred.
  • A strong understanding of the healthcare compliance, legal, and regulatory landscape is required.
  • Demonstrated accountability for results, including focus on strategic objectives, high performance standards, and active participation in leading change.
  • Strategic thinking and problem-solving ability, including considering long-term impacts on customers, patients, employees, and the business.
  • An ongoing focus on the needs of customers and key stakeholders.
  • Ability to communicate with logic, clarity, and respect and influence stakeholders at all levels.
  • Ability to seek and value others' perspectives and develop diverse partnerships toward common goals.
  • An active approach to professional development as a business imperative.
Responsibilities
  • Collaborate with the ecosystem cross-functional team to develop and execute ecosystem strategy that enhances customer satisfaction, improves patient outcomes, and creates business opportunities for Otsuka.
  • Develop and drive the ecosystem commercial strategy.
  • Lead a team of Neuroscience Specialists within an ecosystem to drive appropriate clinical demand and improve patient and customer experiences.
  • Execute and adapt the regional or ecosystem plan to achieve patient-centric objectives, key performance indicators, and performance targets.
  • Scan the industry and broader commercial environment for best practices in the healthcare ecosystem and integrate them through innovative account management processes.
  • Consolidate insights from the field force and other sources, including analytics, to inform regional business plans.
  • Coach Neuroscience Specialists to shape customer plans based on market dynamics, address customer needs, and deliver performance against specialist and ecosystem key performance indicators.
  • Collaborate with ecosystem partners to develop and execute customer engagement strategies and initiatives, gaining insights through external customer interaction, primary and secondary market research, and the field organization.
  • Build, maintain, and leverage networks and relationships in the complex healthcare ecosystem to understand customer needs and priorities and contribute to improved customer, patient, and business outcomes.
  • Partner with senior customers, such as leaders in integrated delivery networks, to maintain ongoing relationships and establish patient-centric platforms for strategic partnership.
  • Understand each customer's needs in pursuing improved patient outcomes, lower costs, and better quality of care by building and leveraging healthcare ecosystem relationships and co-creating solutions.
  • Collaborate across ecosystem roles on shared patient-centric and customer engagement quality goals, including customizing local field deployment and developing ecosystem strategic plans and key performance indicators.
  • Integrate and synthesize knowledge from established relationships to understand the ecosystem and influence the system to improve patient outcomes.
  • Conduct business to high ethical and professional standards consistent with company guidelines and policies, ensuring compliance with regulatory standards in all communications and activities.
  • Drive a high-performance, patient-centric, highly engaged culture within the ecosystem.
  • Foster a collaborative, customer-centric culture that continuously enhances customer engagement, satisfaction, and patient outcomes.
  • Provide adaptive leadership and coaching to support, motivate, and enable the team to deliver the business plan and priorities.
  • Ensure regional sales goals and forecasts align with the organization's long-range strategic objectives.
  • Lead business analysis to identify and recommend strategic opportunities to maximize business results, incorporating input from across Otsuka.
  • Track the ecosystem customer experience formally and informally and use the findings to enhance customer engagement and strategy.
  • Foster a cross-functional account environment that engages customers as solution partners across the portfolio.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.